Table 2.

Changes of clinical characteristics from baseline after 12 weeks of treatment

Variable	HSA group (n=67)	LSA group (n=92)	P-value
IPSS total
Baseline	16.8±6.2	16.6±6.5	0.741
Change from baseline	–3.67±5.61	–3.88±6.04	0.817
Voiding subscore
Baseline	10.4±4.3	10.2±4.9	0.665
Change from baseline	–2.52±4.23	–2.48±4.51	0.964
Storage subscore
Baseline	6.4±3.1	6.5±3.1	0.718
Change from baseline	–1.15±2.08	–1.40±2.33	0.694
Quality of life
Baseline	4.0±0.8	3.6±1.1	0.045
Change from baseline	–0.45±0.97	–0.51±1.29	0.204
Qmax (mL/sec)
Baseline	9.2±3.6	11.3±4.5	0.001
Change from baseline	3.31±6.42	2.63±6.39	0.880
Ratio of PVR (%)
Baseline	11.6±11.7	15.0±15.1	0.174
Change from baseline	–1.81±8.84	–2.95±12.18	0.912
PVR (mL)
Baseline	22.0±25.1	36.6±36.7	0.007
Change from baseline	–0.03±25.24	–9.86±29.81	0.530
IIEF-5
Baseline	12.9±6.6	14.1±7.6	0.219
Change from baseline	1.14±5.34	–0.71±5.04	0.049
OAB-SS
Baseline	3.9±2.4	3.5±2.1	0.310
Change from baseline	–0.40±1.29	–0.17±1.51	0.549
STAI - state anxiety
Baseline	40.8±10.0	39.5±10.8	0.447
Change from baseline	–1.42±5.28	–1.76±6.64	0.837
STAI - trait anxiety
Baseline	41.1±9.7	41.3±11.1	0.903
Change from baseline	–0.46±5.67	–1.73±5.69	0.284

Values are presented as mean±standard deviation.

HSA, high sympathetic activity; LSA, low sympathetic activity; IPSS, International Prostate Symptom Score; Qmax, maximum urinary flow rate; PVR, postvoid residual; IIEF-5, International Index of Erectile Function; OAB-SS, overactive bladder symptom score; STAI, state-trait anxiety inventory.